Clinical Trial Update: Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing nivolumab plus ipilimumab versus ipilimumab alone in previously untreated unresectable or metastatic melanoma has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Unresectable Melanoma, Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2016-02-08